ACOR Acorda Therapeutics

Filed: 2 Jun 21, 6:20am










Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2021


Acorda Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)




420 Saw Mill River Road,

Ardsley, NY



(Address of Principal Executive Offices)


(Zip Code)

Registrant’s Telephone Number, Including Area Code: (914) 347-4300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange on which registered

Common Stock (Par Value $0.001)




Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 






Item 8.01. Other Events.


On June 1, 2021, Acorda Therapeutics, Inc. (the “Company”) issued to the holders of its 6.00% Convertible Senior Secured Notes due 2024 (the “Notes”) an aggregate of 1,635,825 shares of the Company’s common stock (the “Shares”), in satisfaction of approximately $6.2 million in interest due under the Notes on such date. Pursuant to the indenture under which the Notes were issued, the Company may elect to pay interest in cash or shares of the Company’s common stock based on the formula set forth in the indenture. In connection with the issuance of the Shares, an amount corresponding to the $6.2 million of accrued interest will be released from escrow and will be available to the Company for other purposes. The issuance of the Shares was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.



Item 9.01. Financial Statements and Exhibits.


Exhibit No.





Indenture, dated as of December 23, 2019, among the Company, the guarantors party thereto, and Wilmington Trust, National Association, as trustee and collateral agent (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on December 26, 2019).



Form of 6.00% Convertible Senior Secured Notes due 2024 (included in Exhibit 4.1)



Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Acorda Therapeutics, Inc.




June 2, 2021


/s/ Robert Morales



Name: Robert Morales



Title: Vice President, Finance and Controller

and interim principal financial and accounting officer